600645.SS - Vcanbio Cell & Gene Engineering Corp., Ltd

Shanghai - Shanghai Delayed Price. Currency in CNY
17.46
-0.05 (-0.29%)
At close: 3:54PM CST
Stock chart is not supported by your current browser
Previous Close17.51
Open17.52
Bid17.46 x 0
Ask17.47 x 0
Day's Range17.46 - 17.74
52 Week Range14.52 - 23.97
Volume2,146,014
Avg. Volume4,793,116
Market Cap8.171B
Beta (3Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-0.44
Earnings DateOct 26, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2001-08-10
1y Target EstN/A
  • CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
    PR Newswire

    CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer

    ROCKVILLE, Md., April 2, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world, announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer.  Dr. He will continue to serve as Chairman of the Board of Directors.  Dr. He succeeds Ken K. Ren, Ph.D. who for personal reasons is stepping down from his role as Chief Executive Officer but will remain on the Company's Board of Directors.

  • Reuters

    BRIEF-Vcanbio Cell & Gene Engineering Says Chairman Li Defu Resigns

    Dec 7 (Reuters) - Vcanbio Cell & Gene Engineering Corp Ltd : * SAYS CHAIRMAN LI DEFU RESIGNS DUE TO CHANGE IN JOB ROLE Source text in Chinese: https://bit.ly/2B0VTvY Further company coverage: (Reporting ...

  • We're sorry this is all we were able to find about this topic.